<DOC>
	<DOCNO>NCT00004315</DOCNO>
	<brief_summary>OBJECTIVES : I . Compare bioavailability polymer-coated buffer ursodiol ( ursodeoxycholic acid ) unmodified ursodiol patient cystic fibrosis-associated liver disease chronic cholestatic liver disease . II . Compare differences pruritus , weight gain , liver function treatment .</brief_summary>
	<brief_title>Phase II Pilot Study Compare Bioavailability Buffered , Enteric-Coated Ursodiol With Unmodified Ursodiol Chronic Cholestatic Liver Disease Cystic Fibrosis-Associated Liver Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients sequentially treat 2 formulation ursodeoxycholic acid : unmodified ursodiol ( Actigall ) buffer , enteric-coated ursodiol ( Ursocarb ) . There 24-hour washout 4-week course therapy .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Chronic cholestatic liver disease Cystic fibrosisassociated liver disease Prior/Concurrent Therapy Usual customary diet maintain throughout study , e.g. , mediumchain triglyceride oil Patient Characteristics Pulmonary : No serious respiratory deficiency No acute illness No inability swallow No fertile woman</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2002</verification_date>
	<keyword>cardiovascular respiratory disease</keyword>
	<keyword>cholestasis</keyword>
	<keyword>cystic fibrosis</keyword>
	<keyword>gastrointestinal disorder</keyword>
	<keyword>genetic disease dysmorphic syndrome</keyword>
	<keyword>rare disease</keyword>
</DOC>